1. Home
  2. ARTL vs RDHL Comparison

ARTL vs RDHL Comparison

Compare ARTL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$0.88

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.73

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
RDHL
Founded
2011
2009
Country
United States
Israel
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
ARTL
RDHL
Price
$0.88
$0.73
Analyst Decision
Hold
Analyst Count
2
0
Target Price
N/A
N/A
AVG Volume (30 Days)
166.5K
63.6K
Earning Date
05-13-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$381.91
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.96
$0.63
52 Week High
$19.91
$2.79

Technical Indicators

Market Signals
Indicator
ARTL
RDHL
Relative Strength Index (RSI) 30.26 46.33
Support Level N/A $0.71
Resistance Level $1.24 $0.91
Average True Range (ATR) 0.07 0.06
MACD 0.02 0.01
Stochastic Oscillator 0.00 62.50

Price Performance

Historical Comparison
ARTL
RDHL

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Share on Social Networks: